Abstract: The present invention provides novel C24-sulfone analogs of 1?,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Abstract: Described is a triggering arrangement including a power supply, a lighting arrangement and a switch. The lighting arrangement is coupled to the power supply. The switch is coupled to the lighting arrangement and the power supply. When the switch is in a first position, the lighting arrangement generates light to a photo-sensing portable device. The device is situated a predetermined distance from the arrangement. The device initiates a predetermined action in response to the light.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders and cancer.

Abstract: The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1?,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Abstract: A system for transferring data between a centrally located site and a portable communications terminal via a telephone network, the site having associated therewith a look up table containing plurality of data records correlating to items disposed at a retail establishment, wherein each of the items has associated therewith a bar code encoded with the indicia unique to each item, with each of the bar coded indicia corresponding to a particular record in the table, the data containing at least a portion of said record.

Abstract: A tire inflation system includes an air supply source in selective fluid communication with a tire via a pneumatic conduit. A method of inflating the system includes providing a tire pressure retention valve in the pneumatic conduit adjacent to the tire. An inflation pressure of the tire is determined with a step-up procedure, in which air bursts are communicated from the air supply source to a portion of the pneumatic conduit between the air supply source and the tire pressure retention valve. The volume of at least one selected communicated air burst is related to a volume of a section of the conduit. The tire is inflated with an extended-pulse procedure, in which extended bursts of air are communicated from the air supply source to the tire. A shut-down sequence is performed once a predetermined target inflation pressure in the tire is reached.

Abstract: Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.

Abstract: Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.

Abstract: Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.

Abstract: The present invention provides novel D-ring and side-chain analogs of 1&agr;,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.

Abstract: The present invention is directed to a method of assembling a container including an inner tube contained within an outer tube. The method includes providing an outer tube, providing a spacing element adjacent the open top of the outer tube and inserting an inner tube within the outer tube. The spacing element provides for venting of air from between the inner and outer tubes through the top of the container during assembly thereof.

Abstract: The present invention provides novel C24-sulfone analogs of 1&agr;,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.

Abstract: The present invention relates to a novel human gene encoding a polypeptide that is a member of the cytochrome P450 family. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named cytochrome P450TEC (Thymus Expressed Cytochrome). This invention also relates to P450TEC polypeptides, as well as vectors, host cells, and antibodies directed to P450TEC polypeptides, and the recombinant methods for producing the same. Also provided are therapeutic methods for treating P450TEC-related disorders. The invention further relates to screening methods for identifying agonists and antagonists of P450TEC activity.

Abstract: The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1&agr;,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Abstract: The present invention provides novel C24-aryl sulfone analogs of 1&agr;,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Abstract: A method of selecting a performance golf club based on a golfer's swing type is accomplished in an automated fashion, comprising a system that is readily and easily utilized in a retail setting, for example. The golfer performs several swings of a golf club before a digital camera that transmits the golfer's swing information to a computational device for processing. Several parameters relating to the golfer's swing characteristics are identified and a performance golf club is selected and displayed for the golfer within less than one hour, and preferably within about five to ten minutes. Markers may be positioned on the golf club and/or golfer for easier tracking and data collection by the present system.

Abstract: Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.